Results 81 to 90 of about 16,934 (220)
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young +10 more
wiley +1 more source
Impact of standardized endoscopic imaging on early detection rate of upper gastrointestinal tract cancer: A quasi-experimental study. [PDF]
Zhang ZX +4 more
europepmc +1 more source
Abstract Objectives We aimed at identifying magnetic resonance enterography (MRE) predictors of surgical intervention and anti‐tumor necrosis factor alpha (TNF‐α) initiation in a paediatric cohort of patients newly diagnosed with isolated ileocaecal (L1) Crohn's disease (CD).
Saverio Pochesci +8 more
wiley +1 more source
Endoscopic findings in patients with chronic bloating/abdominal distension and the effect of the transition from the Rome III to Rome IV criteria: a multicenter cross-sectional study. [PDF]
Wu J, Xu Z, Bai T, Hou X, Song J.
europepmc +1 more source
Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome
Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski +5 more
wiley +1 more source
Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy. [PDF]
Kuang AG +11 more
europepmc +1 more source
Case series: Joubert syndrome and eosinophilic esophagitis
Abstract Joubert syndrome (JS) is a rare genetic disorder characterized by developmental abnormalities, particularly in the brainstem and cerebellar vermis, alongside multisystem manifestations such as kidney and liver anomalies, polydactyly, cleft lip or palate, and tongue defects.
Jonathon Schening +5 more
wiley +1 more source

